Bayer did leave the door open to a resumption of sales, but said this would involve “extensive discussions” with regulatory authorities. In Canada, 1.3 million prescriptions have been filled since the drug was introduced in 1998, and a company spokesperson said it was enjoying “growing market share.” In withdrawing the drug, the company said it would no longer be able to meet the target of a 20% return on sales it had set for 2002.